Investigators Meeting 2011

Date: 14 May, 2011
Venue: The Empire Hotel, Hong Kong

OOTR Investigator's Meeting was held on 14th May 2011 at the Platino Room, Empire Hotel in Hong Kong. Dr. Louis Chow, Honorary Clinical Professor of the University of Hong Kong and Executive Director of OOTR, welcomed the investigators from different countries to meet and discuss the progress of existing clinical trials. Dr. Hironobu Sasano, Professor of Pathology Department at Tohoku University School of Medicine, has shared with us the surrogate endpoints of neoadjuvant chemotherapy, the definition of pathologic complete response and some new surrogate biomarkers. Dr. Raymond Chan, Consultant & Honorary Clinical Associate Professor from the Queen Mary Hospital, also addressed us the issues of assessing cardiotoxicity for chemotherapy, and also the incidences of different cardiac problems.


After the lectures by Dr. Sasano and Dr. Chan, Dr. Chow has shared the results in terms of efficacy and safety of OOTR-N001, such as the change in cardiac function, and also the comments and recommendations from the IDMC. Dr. Chow has also emphasized the importance of pathologic response rate, which has to be confirmed by the central pathology review.


As for OOTR-N003 trial, Dr. Masakazu Toi, Professor of Breast Surgery Department at Graduate School of Medicine in Kyoto University and President of OOTR, stated that the pathological assessment has already started and the next step will be staining the high priority markers. After that Dr. Chow has shared the progress of the Tubulin Study, he concluded that breast tumours might have a lower chance of resistance to taxane-based chemotherapy, which could be widely used in Asian breast cancer patients. And lastly, Dr. Chow talked about the progress of the OOTR-N006 study. 


Looking beyond the well-presented results of the OOTR studies will yield insights as we look to the future of translational research. Predictive and Prognostic markers are key issues in cancer therapeutics. Since tumour samples from OOTR-N001, OOTR-N003, and OOTR-N006 studies are already available, Dr. Chow has suggested fully utilising these samples in discovering the new predictive and prognostic markers. These markers would definitely aid the diagnosis and treatment of breast cancer in the future.  



(Summarised by Wai-pui Chu and Adrian Yip, OOTR)